QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Filing for WHO Emergency Use Authorisation this month
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
Board approves fundraise of Rs 1500 crore
The transaction is expected to close in the Q4FY22
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
The data should be submitted by August 12th 2021
It is part of the company’s pain/analgesics portfolio of OTC products
Startup receives US $ 5 million in first round of funding
Subscribe To Our Newsletter & Stay Updated
